Translucence Co-Founders Damian Wheeler, Ph.D. and Sunil Gandhi, Ph.D. along with their colleagues Chase Redd and Nathaniel Guanzon recently presented at the Alzheimer's Association International Conference® 2022. To help move AD drug discovery forward, Translucence has developed whole-brain regional assays for β-Amyloid plaques and microglia and with Lundbeck, methods to measure antibody therapeutics crossing the Blood-Brain Barrier and homing in on their target.
Access the "Brain Wide Monitoring of Antibody Therapeutics Crossing the Blood/Brain Barrier" poster here.
Access the "Brain-Wide Cellular Resolution Regional Quantification of Microglia and Amyloid in 5xfad Mice" poster here.
Ask your question
Send us your questions and we will get back to you as soon as possible